<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The method of immune-enzyme assay was used to examine 113 patients with secondary <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo>, including 16 HIV-infected drug-addicts (group 1), 36 patients with <z:e sem="disease" ids="C0010823" disease_type="Disease or Syndrome" abbrv="">cytomegalovirus infection</z:e> (CMVI) and with immunoregating index CD4/CD8 below 1.0 (group 2), 30 patients with CMVI and with CD4/CD8 below 1.2 (group 3) and 31 patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> and with <z:hpo ids='HP_0001903'>anemia</z:hpo> of unclear genesis (group 4), for <z:e sem="disease" ids="C0205882" disease_type="Disease or Syndrome" abbrv="">parvovirus infection</z:e> caused by parvovirus B19 </plain></SENT>
<SENT sid="1" pm="."><plain>As for groups 1 and 4, the antibodies were detected in 50 and 48.4% of cases; it is noteworthy that an active <z:e sem="disease" ids="C0205882" disease_type="Disease or Syndrome" abbrv="">parvovirus infection</z:e> was registered in the above groups more often than in groups 2 and 3 </plain></SENT>
<SENT sid="2" pm="."><plain>There were patients with the antibodies in group 2 by 1.8 times more than in group 3 </plain></SENT>
<SENT sid="3" pm="."><plain>It is suggested that the simultaneous impact of HIV, CMV and parvoviruses significantly aggravates the <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> and contributes to a more severe clinical course </plain></SENT>
</text></document>